Evidence map›Paper›PMID 42144449›Full record

ArticleActa pharmacologica Sinica2026

Correction: Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.

Min Tian, Xi-Sha Chen, Lan-Ya Li, Hai-Zhou Wu, Da Zeng, Xin-Luan Wang, Yi Zhang, Song-Shu Xiao, Yan Cheng

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Min TianDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Xi-Sha ChenDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Lan-Ya LiDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Hai-Zhou WuDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Da ZengDepartment of Gynecology and Obstetrics, The Third Xiangya Hospital, Central South University, Changsha, China.
Xin-Luan WangTranslational Medicine R&D Center, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Yi ZhangDepartment of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
Song-Shu XiaoDepartment of Gynecology and Obstetrics, The Third Xiangya Hospital, Central South University, Changsha, China. xiaosongshu@csu.edu.cn.
Yan ChengDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China. yancheng@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42144449
PMCPMC13487300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.